Neurogene Inc. Accounts Payable and Other Accrued Liabilities, Current
Neurogene Inc. (NGNE) had Accounts Payable and Other Accrued Liabilities, Current of $9.55 million as of 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2023-03-20
- 2022-12-31: Accounts Payable and Other Accrued Liabilities, Current $9.55M.
- 2021-12-31: Accounts Payable and Other Accrued Liabilities, Current $7.42M.
- 2020-12-31: Accounts Payable and Other Accrued Liabilities, Current $7.18M.
- 2020-03-31: Accounts Payable and Other Accrued Liabilities, Current $5.00M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current | Accounts Payable and Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2022-12-31 | $9.55M 10-K · filed 2023-03-20 | |
| 2021-12-31 | $7.42M 10-K · filed 2023-03-20 | |
| 2020-12-31 | $7.18M 10-K · filed 2022-03-01 | |
| 2020-03-31 | $5.00M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $4.13M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $2.30M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $958.00K 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $3.40M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $4.62M 10-K · filed 2020-03-12 | $4.63M 10-K · filed 2019-03-07 |
| 2018-09-30 | $10.75M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $13.35M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $9.36M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $10.96M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $7.00M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $8.13M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $5.82M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $9.52M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $8.56M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $8.50M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $5.72M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $4.79M 10-K · filed 2017-03-09 | |
| 2014-12-31 | $5.20M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |